ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Magnus Corfitzen, CEO presenting at Redeye event in Malmö 12 Sep 2019

Download our Ascelia Pharma Fact sheet

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• February 14 @ 08:00

  Financial report Oct-Dec 2019

• May 6 @ 11:00 - 13:00

  Annual General Meeting 2020

• May 13 @ 08:00

  Interim financial report Q1 2020 (Jan-Mar)

• August 20 @ 08:00

  Half-year financial report 2020 (Jan-Jun)

• November 5 @ 08:00

  Interim financial report 9M 2020 (Jan-Sep)

• 2020-01-13Five sites now opened in the pivotal Phase III clinical study SPARKLE for lead drug candidate Mangoral
• 2019-12-18Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB
• 2019-12-06Ascelia Pharma appoints Julie Waras Brogren as Chief Commercial Officer
• 2019-11-14Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019
• 2019-11-08Q1 2019/2020 Financial Report: Preparations for Phase III study with Mangoral® on track